Mauna Kea Technologies SAS
PAR:MKEA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Mauna Kea Technologies SAS
Accrued Liabilities
Mauna Kea Technologies SAS
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Mauna Kea Technologies SAS
PAR:MKEA
|
Accrued Liabilities
€1.8m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Edap Tms SA
NASDAQ:EDAP
|
Accrued Liabilities
€9.8m
|
CAGR 3-Years
11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
8%
|
|
|
Biomerieux SA
PAR:BIM
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
SMAIO SA
PAR:ALSMA
|
Accrued Liabilities
€767.4k
|
CAGR 3-Years
16%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Amplitude Surgical SA
PAR:AMPLI
|
Accrued Liabilities
€9.4m
|
CAGR 3-Years
11%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Mauna Kea Technologies SA
PAR:ALMKT
|
Accrued Liabilities
€2.2m
|
CAGR 3-Years
23%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
1%
|
|
Mauna Kea Technologies SAS
Glance View
Mauna Kea Technologies SA engages in the design, development, and sale of optical biopsy devices and tools to visualize and detect abnormalities in the gastro-intestinal and pulmonary tracts primarily in cancer patients. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2011-07-05. The firm focuses on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product is Cellvizio, a confocal laser endomicroscopy platform using microprobes and needles. This technological platform enables to view tissues at cellular level, in real time, during standard procedure. Cellvizio can be used in gastroenterology, pulmonology, or urology. The firm markets its technological platform in more than 40 countries, including the United States, Europe, Japan, China, South Korea as well as several Latin American countries.
See Also
What is Mauna Kea Technologies SAS's Accrued Liabilities?
Accrued Liabilities
1.8m
EUR
Based on the financial report for Dec 31, 2022, Mauna Kea Technologies SAS's Accrued Liabilities amounts to 1.8m EUR.
What is Mauna Kea Technologies SAS's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
5%
Over the last year, the Accrued Liabilities growth was 0%. The average annual Accrued Liabilities growth rates for Mauna Kea Technologies SAS have been -10% over the past three years , 5% over the past five years .
